ASSESSMENTS

A Resolution on Who Owns Gene Editing

Feb 16, 2017 | 23:34 GMT

The CRISPR-Cas9 gene editing complex from Streptococcus pyogenes. Technologies such as CRISPR have wide-ranging implications for agriculture, industrial biotechnology and human health care. The fight for ownership of the powerful gene-editing technique known as CRISPR-Cas9 is over, at least for now. The victor in the patent case, however, is less important than the fact that policy continues to lag behind scientific progress.
The CRISPR-Cas9 gene editing complex from Streptococcus pyogenes. Technologies such as CRISPR have wide-ranging implications for agriculture, industrial biotechnology and human health care. The fight for ownership of the powerful gene-editing technique known as CRISPR-Cas9 is over, at least for now. The victor in the patent case, however, is less important than the fact that policy continues to lag behind scientific progress.

(MOLEKUUL_BE/Shutterstock)

The fight for ownership of the powerful gene-editing technique known as CRISPR-Cas9 is over, at least for now. A panel of judges at the U.S. Patent and Trademark Office ruled Feb. 15 in favor of the Broad Institute of the Massachusetts Institute of Technology and Harvard, despite the fact that the University of California, Berkeley, had pioneered the technique using less complex bacterial systems....

Subscribe to view this article

Subscribe Now

Subscribe

Already have an account?